Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$227.97−4.26 (-1.83%)
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Biotechnology — GAAP Sales Growth by Quarter
Biotechnology — GAAP Sales Growth (%)
Danaher Biotechnology — GAAP Sales Growth: 0.5% in Q3 2026, down 8.5 pts from a year earlier.
Latest, Q3 2026
0.5%
Period ended Sep 30, 2026
Change on a year earlier
-8.5 pts
9.0% in Q3 2025
History
20 quarters
Since Q4 2021
Sources
13
Documents cited below
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Reported in Danaher Non-GAAP Reconciliations & Supplemental Data (8-K / IR PDF).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biotechnology — GAAP Sales Growth (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 0.5% | -8.5 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 4.0% | -4.0 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 11.5% | +5.5 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 9.0% | +2.5 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 9.0% | +9.5 pts | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 8.0% | +17.0 pts | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 6.0% | +24.0 pts | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 6.5% | +27.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | -0.5% | +18.5 pts | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | -9.0% | +8.0 pts | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | -18.0% | -2.0 pts | Danaher IR — nongaap_2024Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | -21.0% | -20.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | -19.0% | -18.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | -17.0% | -21.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | -16.0% | -22.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | -1.0% | -63.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | -0.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 4.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 6.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | 62.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher Biotechnology — GAAP Sales Growth (%), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/gaap-sales-growth-biotech
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.